12 results about "GnRH Antagonist" patented technology

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.

The present invention relates to the field of GnRH antagonists and anti-GnRH ligands. The invention also relates to the fields of pharmacy and diagnosis. In particular, the present disclosure relates to the field of contraception and GnRH-related diseases.

The present invention relates to the field of mammalian reproduction and use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

The present invention relates to the field of mammalian reproduction. Disclosed is use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent use, and can be used for estrus synchronization and batch reproduction of livestock husbandry animals or regulation and control of estrus of pets.

The invention relates to an oral dosage unit for use in a method of contraception in a human male, said oral dosage units containing GnRH antagonist and dehydroepiandrosterone (DHEA), the method comprising once daily oral administration of the oral dosage unit to the human male during a period of at least 7 days. This contraceptive method is convenient, effectively suppresses spermatogenesis and is reversible. Another aspect of the invention relates to a dosage unit comprising: • GnRH antagonist selected from: o 50-250 mg relugolix; o 167-833 mg linzagolix; o 113-583 mg elagolix; • 100-800 mg dehydroepiandrosterone.

The present disclosure relates to methods for reproductive management of mammalian animals using a GnRH antagonist such as Cetrorelix. Specifically, the GnRH antagonist can be used for synchronizing follicular wave emergence in a population of female mammals, and / or for fixed-time reproductive management protocols such as oocyte collection protocols, embryo collection protocols, artificial insemination protocols or embryo transfer protocols. Also described are devices and kits for reproductive management, comprising a GnRH antagonist and optionally one or more additional drugs useful for reproductive management.

The present disclosure provides compositions and methods for treating endometrial growth disorders in a patient, such as a human patient, and particularly pre-menopausal female human patients. Exemplary disorders that may be treated using the compounds and therapeutic regimens described herein include adenomyosis and rectovaginal endometriosis. The compounds described herein that may be used to treat such indications include gonadotropin-releasing hormone (GnRH) antagonists. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof, among others.

The invention belongs to the field of biological medicine, and particularly relates to a long-acting GnRH antagonist and a composition containing the same. According to the invention, a component with GnRH antagonistic activity is wrapped in a small apoptotic body derived from pituitary tumor cells, and it is found that the obtained preparation unexpectedly endows the active component with a longer in-vivo plasma half-life period; formulations prepared using small apoptotic bodies derived from other cell types such as mesenchymal stem cells, melanoma cells do not have this effect. On the basis, the GnRH antagonist disclosed by the invention can be further encapsulated in sustained-release microspheres, so that the in-vivo release behavior and bioavailability of the GnRH antagonist can be further optimized.

The present invention relates to a composition comprising at least one GnRH antagonist for use in reducing the risk of recurrent acute urinary retention (AUR) in males of least 45 years of age presenting with a first episode of AUR. Said composition can within four week effectively alleviate urethral obstruction caused by an enlarged prostate, and restore normal urine flow without the need for surgery.

The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in post-puberal PCOS affected individuals.

The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

The present invention generally relates to the field of GnRH antagonist formulations. More particularly, the invention relates to pharmaceutical compositions made of microparticles for the slow release of a GnRH antagonist, such as degarelix, medical uses of such pharmaceutical compositions, a kit including such pharmaceutical compositions and methods for the preparation of such pharmaceutical compositions.